# Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

> **NCT05676450** · NA · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 517 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DIAGNOSTIC_TEST:** cell-free DNA

## Key facts

- **NCT ID:** NCT05676450
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-23
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 517 (ESTIMATED)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676450, "Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05676450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*